Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy

Journal of Medicinal Chemistry

Volumn 55, Issue 15, 2012, Pages 6784-6801

  Qin, Zhihui ^a   Luo, Jia ^a   Vandevrede, Lawren ^a   Tavassoli, Ehsan ^a   Fa, Mauro ^b   Teich, Andrew F ^b   Arancio, Ottavio ^b   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHYL 5 THIAZOLYL) 1 (4 CHLOROPHENYL)METHANOL; 1 (4 METHYL 5 THIAZOLYL) 1 (4 FLUOROPHENYL)METHANOL; 1 (4 METHYL 5 THIAZOLYL) 1 PHENYLMETHANOL; 2,3,4,5 TETRAHYDRO 2,8 DIMETHYL 5 [2 (4 METHYL 5 THIAZOLYL) ETHYL] 1H PYRIDO[4,3 BETA]INDOLE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 METHYLTHIAZOLE DERIVATIVE; 5 (2 AZIDOETHYL) 4 METHYLTHIAZOLE; 5 (METHOXYPHENYLMETHYL) 4 METHYLTHIAZOLE; [1 [BETA (4 METHYL 5 THIAZOLYL)ETHANOL] 4 (3 PYRIDINYL)] 1H 1,2,3 TRIAZOLE; [2 [(4 METHYL 5 THIAZOLYL)PHENYLMETHOXY]ETHOXY]ETHANOL; ALPHA (PHENYLMETHYL) 4 METHYL 5 THIAZOLEMETHANOL; ALPHA [(4 FLUOROPHENYL)METHYL] 4 METHYL 5 THIAZOLEMETHANOL; BETA (4 FLUOROPHENYL) 4 METHYL 5 THIAZOLEETHANOL; BETA AZIDO 4 METHYL 5 THIAZOLEETHANOL; BETA PHENYL (4 METHYL 5 THIAZOLYL)ETHANE 1 NITRATE; BETA PHENYL 4 METHYL 5 THIAZOLEETHANOL; NEUROPROTECTIVE AGENT; PRODRUG; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL HYPOXIA; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; EXCITOTOXICITY; HIPPOCAMPUS; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; RAT; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AVOIDANCE LEARNING; BIOLOGICAL AVAILABILITY; BRAIN; CLICK CHEMISTRY; COGNITION DISORDERS; GLUCOSE; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR MIMICRY; MUTATION; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; OXYGEN; PRIMARY CELL CULTURE; PRODRUGS; RECEPTORS, GABA-A; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC TRANSMISSION; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84864943292     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300353r     Document Type: Article

References (95)

1. Wimo, A.; Winblad, B.; Jonsson, L. The worldwide societal costs of dementia: estimates for 2009 Alzheimer's Dement 2010, 6, 98-103
2. Cummings, J. L. Alzheimers disease N. Engl. J. Med. 2004, 351, 56-67
3. Selkoe, D. J. Resolving controversies on the path to Alzheimers therapeutics Nat. Med. 2011, 17, 1060-1065
4. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimers disease: clinical trials and drug development Lancet Neurol. 2010, 9, 702-716
5. Citron, M. Alzheimers disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9, 387-398
6. Nelson, R. M.; Hainsworth, A. H.; Lambert, D. G.; Jones, J. A.; Murray, T. K.; Richards, D. A.; Gabrielsson, J.; Cross, A. J.; Green, A. R. Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro Neuropharmacology 2001, 41, 159-166
7. Green, A. R.; Hainsworth, A. H.; Misra, A.; Debens, T. A.; Jackson, D. M.; Murray, T. K.; Nelson, R. M.; Cross, A. J. The interaction of AR-A008055 and its enantiomers with the GABA(A) receptor complex and their sedative, muscle relaxant and anticonvulsant activity Neuropharmacology 2001, 41, 167-174
8. Colado, M. I.; OShea, E.; Esteban, B.; Green, A. R. Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ("ecstasy" )-induced neurodegeneration in rat brain Psychopharmacology 2001, 157, 82-88
9. Lechat, P.; Streichenberger, G.; Boime, A.; Lemeignan, M. Relation between chemical structure and physiological activity of certain thiazole derivatives. I. 4-Methyl-5-(β-hydroxyethyl)thiazole Ann. Pharm. Fr. 1965, 23, 179-186
10. Lechat, P.; Streichenberger, G.; Boime, A.; Lemeignan, M. Relations between the chemical structure and physiological activity of certain thiazole derivatives. II. Effect of the length of the alkyl chain in 4-methyl-5-(ω- chloroalkyl)thiazoles Ann. Pharm. Fr. 1965, 23, 369-576
11. Lechat, P.; van den Driessche, J.; Lemeignan, M.; Deleau, D. Pharmacological investigation of a quaternary ammonium compound with ganglion-exciting properties Arch. Int. Pharmacodyn. Ther. 1965, 155, 262-272
12. Bengtsson, S.; Lindberg, U. H. Compounds related to clomethiazole. VI. Synthesis of some reference compounds in connection with biotransformation studies Acta Pharm. Suec. 1982, 19, 37-42
13. Lindberg, U. H. Compounds related to clomethiazole. I. Oxazole and pyridine isosteres of clomethiazole Acta Pharm. Suec. 1966, 3, 161-166
14. Lindberg, U. H.; Pedersen, J.; Ulff, B. Compounds related to clomethiazole. II. Haloalkyl and aminoalkyl analogs of clomethiazole Acta Pharm. Suec. 1967, 4, 269-280
15. Lindberg, U. H. Hypnotic and anticonvulsant agents related to the thiazole part of thiamine Acta Pharm. Suec. 1971, 8, 647-660
16. Lindberg, U. H. Compounds related to clomethiazole. IV. 4-Methylthiazoles and oxazoles with polar side-chains and some other analogs of clomethiazole Acta Pharm. Suec. 1971, 8, 39-48
17. Lindberg, U. H.; Bexell, G.; Ulff, B. Compounds related to clomethiazole. V. 4-(Alkyl or aryl) thiazoles and oxazoles with various substituents in the 2- and 5-positions Acta Pharm. Suec. 1971, 8, 49-58
18. Green, A. R. Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy Pharmacol. Ther. 1998, 80, 123-147
19. Marshall, J. W.; Cross, A. J.; Ridley, R. M. Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species Exp. Neurol. 1999, 156, 121-129
20. Farooque, M.; Isaksson, J.; Jackson, D. M.; Olsson, Y. Clomethiazole (ZENDRA, CMZ) improves hind limb motor function and reduces neuronal damage after severe spinal cord injury in rat Acta Neuropathol. 1999, 98, 22-30
21. Wahlgren, N. G.; Diez-Tejedor, E.; Teitelbaum, J.; Arboix, A.; Leys, D.; Ashwood, T.; Grossman, E. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients Stroke 2000, 31, 82-85
22. Wahlgren, N. G.; Ranasinha, K. W.; Rosolacci, T.; Franke, C. L.; van Erven, P. M.; Ashwood, T.; Claesson, L. Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients Stroke 1999, 30, 21-28
23. Mucke, H. Clomethiazole (Astra Arcus AB) IDrugs 1999, 2, 184-193
24. Lyden, P.; Jacoby, M.; Schim, J.; Albers, G.; Mazzeo, P.; Ashwood, T.; Nordlund, A.; Odergren, T. The clomethiazole acute stroke study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results Neurology 2001, 57, 1199-1205
25. Lyden, P.; Shuaib, A.; Ng, K.; Levin, K.; Atkinson, R. P.; Rajput, A.; Wechsler, L.; Ashwood, T.; Claesson, L.; Odergren, T.; Salazar-Grueso, E. Clomethiazole acute stroke study in ischemic stroke (CLASS-I): final results Stroke 2002, 33, 122-128
26. Wilby, M. J.; Hutchinson, P. J. The pharmacology of chlormethiazole: a potential neuroprotective agent? CNS Drug Rev. 2004, 10, 281-294
27. Harmon, D.; Coleman, E.; Marshall, C.; Lan, W.; Shorten, G. The effect of clomethiazole on plasma concentrations of interleukin-6, -8, -1beta, tumor necrosis factor-alpha, and neutrophil adhesion molecule expression during experimental extracorporeal circulation Anesth. Analg. 2003, 97, 13-18
28. Clarkson, A. N.; Liu, H.; Rahman, R.; Jackson, D. M.; Appleton, I.; Kerr, D. S. Clomethiazole: mechanisms underlying lasting neuroprotection following hypoxia-ischemia FASEB J. 2005, 19, 1036-1038
29. Clarkson, A. N.; Clarkson, J.; Jackson, D. M.; Sammut, I. A. Mitochondrial involvement in transhemispheric diaschisis following hypoxia-ischemia: clomethiazole-mediated amelioration Neuroscience 2007, 144, 547-561
30. Shi, J. Q.; Shen, W.; Chen, J.; Wang, B. R.; Zhong, L. L.; Zhu, Y. W.; Zhu, H. Q.; Zhang, Q. Q.; Zhang, Y. D.; Xu, J. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains Brain Res. 2011, 1368, 239-247
31. Alvarez, A.; Cacabelos, R.; Sanpedro, C.; Garcia-Fantini, M.; Aleixandre, M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease Neurobiol. Aging 2007, 28, 533-536
32. McAlpine, F. E.; Lee, J. K.; Harms, A. S.; Ruhn, K. A.; Blurton-Jones, M.; Hong, J.; Das, P.; Golde, T. E.; LaFerla, F. M.; Oddo, S.; Blesch, A.; Tansey, M. G. Inhibition of soluble TNF signaling in a mouse model of Alzheimers disease prevents pre-plaque amyloid-associated neuropathology Neurobiol. Dis. 2009, 34, 163-177
33. Strum, J. C.; Shehee, R.; Virley, D.; Richardson, J.; Mattie, M.; Selley, P.; Ghosh, S.; Nock, C.; Saunders, A.; Roses, A. Rosiglitazone induces mitochondrial biogenesis in mouse brain J. Alzheimer's Dis. 2007, 11, 45-51
34. Santos, R. X.; Correia, S. C.; Carvalho, C.; Cardoso, S.; Santos, M. S.; Moreira, P. I. Mitophagy in neurodegeneration: an opportunity for therapy? Curr. Drug Targets 2011, 12, 790-799
35. Selkoe, D. J. Alzheimers disease is a synaptic failure Science 2002, 298, 789-91
36. Thatcher, G. R. J.; Bennett, B. M.; Reynolds, J. N. NO chimeras as therapeutic agents in Alzheimers disease Curr. Alzheimer Res. 2006, 3, 237-245
37. Bennett, B. M.; Reynolds, J. N.; Prusky, G. T.; Douglas, R. M.; Sutherland, R. J.; Thatcher, G. R. J. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester Neuropsychopharmacology 2007, 32, 505-513
38. Puzzo, D.; Staniszewski, A.; Deng, S. X.; Privitera, L.; Leznik, E.; Liu, S.; Zhang, H.; Feng, Y.; Palmeri, A.; Landry, D. W.; Arancio, O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimers disease mouse model J. Neurosci. 2009, 29, 8075-8086
39. Saura, C. A.; Valero, J. The role of CREB signaling in Alzheimers disease and other cognitive disorders Rev. Neurosci. 2011, 22, 153-169
40. Espana, J.; Valero, J.; Minano-Molina, A. J.; Masgrau, R.; Martin, E.; Guardia-Laguarta, C.; Lleo, A.; Gimenez-Llort, L.; Rodriguez-Alvarez, J.; Saura, C. A. beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1 J. Neurosci. 2010, 30, 9402-9410
41. Wang, A.; Bibb, J. A. Is CREB the angry bird that releases memory in alzheimers? Neuropsychopharmacology 2011, 36, 2153-2154
42. Pugazhenthi, S.; Wang, M.; Pham, S.; Sze, C. I.; Eckman, C. B. Downregulation of CREB expression in Alzheimers brain and in Abeta-treated rat hippocampal neurons Mol. Neurodegener. 2011, 6, 60
43. Yiu, A. P.; Rashid, A. J.; Josselyn, S. A. Increasing CREB function in the CA1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimers disease Neuropsychopharmacology 2011, 36, 2169-2186
44. Lu, Y. F.; Kandel, E. R.; Hawkins, R. D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus J. Neurosci. 1999, 19, 10250-10261
45. Riccio, A.; Alvania, R. S.; Lonze, B. E.; Ramanan, N.; Kim, T.; Huang, Y.; Dawson, T. M.; Snyder, S. H.; Ginty, D. D. A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons Mol. Cell 2006, 21, 283-294
46. Zhuo, M.; Hu, Y.; Schultz, C.; Kandel, E. R.; Hawkins, R. D. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation Nature 1994, 368, 635-639
47. Puzzo, D.; Vitolo, O.; Trinchese, F.; Jacob, J. P.; Palmeri, A.; Arancio, O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity J. Neurosci. 2005, 25, 6887-6897
48. Puzzo, D.; Palmeri, A.; Arancio, O. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimers disease Rev. Neurosci. 2006, 17, 497-523
49. Paul, C.; Stratil, C.; Hofmann, F.; Kleppisch, T. cGMP-dependent protein kinase type I promotes CREB/CRE-mediated gene expression in neurons of the lateral amygdala Neurosci. Lett. 2010, 473, 82-86
50. Thatcher, G. R. J.; Bennett, B. M.; Reynolds, J. N. Nitric oxide mimetic molecules as therapeutic agents in Alzheimers disease Curr. Alzheimer Res. 2005, 2, 171-182
51. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. 2002, 41, 2596-2599
52. Tornoe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides J. Org. Chem. 2002, 67, 3057-3064
53. Moorhouse, A. D.; Moses, J. E. Click chemistry and medicinal chemistry: a case of "cyclo-addiction" ChemMedChem 2008, 3, 715-723
54. Jones, R. W. Dimebon disappointment Alzheimer's Res. Ther. 2010, 2, 25
55. Lizarzaburu, M. E.; Shuttleworth, S. J. 1,2,3,4-Tetrahydro- c -carbolinium salts: novel reactions with thiols, mediated by polymer-supported reagents Tetrahedron Lett. 2004, 45, 4781-4783
56. Charonnat, R.; Lechat, P.; Chareton, J. From a convulsive to an anticonvulsive product in the thiamine series Therapie 1956, 11, 261-264
57. Ogren, S. O. Chlormethiazole - mode of action Acta Psychiatr. Scand., Suppl. 1986, 329, 13-27
58. Hedlund, B.; Ogren, S. O. Chlormethiazole acts on chloride channels in cultured spinal cord neurons Neurosci. Lett. 1987, 78, 217-221
59. Nelson, R. M.; Green, A. R.; Hainsworth, A. H. Electrophysiological actions of γ-aminobutyric acid and clomethiazole on recombinant GABAA receptors Eur. J. Pharmacol. 2002, 452, 255-262
60. Marshall, J. W.; Cross, A. J.; Jackson, D. M.; Green, A. R.; Baker, H. F.; Ridley, R. M. Clomethiazole protects against hemineglect in a primate model of stroke Brain Res. Bull. 2000, 52, 21-29
61. Gilby, K. L.; Sydserff, S. G.; Robertson, H. A. Differential neuroprotective effects for three GABA-potentiating compounds in a model of hypoxia-ischemia Brain Res. 2005, 1035, 196-205
62. Wang, Q.; Walsh, D. M.; Rowan, M. J.; Selkoe, D. J.; Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5 J. Neurosci. 2004, 24, 3370-3378
63. Rowan, M. J.; Klyubin, I.; Wang, Q.; Anwyl, R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity Exp. Gerontol. 2004, 39, 1661-1667
64. Green, A. R.; Murray, T. K.; Misra, A.; Snape, M. F.; Jones, J. A.; Cross, A. J. The metabolism of clomethiazole in gerbils and the neuroprotective and sedative activity of the metabolites Br. J. Pharmacol. 2000, 129, 95-100
65. Ende, M.; Spiteller, G.; Remberg, G.; Heipertz, R. Urinary metabolites of clomethiazole. Detection and structural analysis by gas chromatography-mass spectrometry Arzneim. Forsch. 1979, 29, 1655-8
66. Simi, A.; Ingelman-Sundberg, M.; Tindberg, N. Neuroprotective agent chlomethiazole attenuates c-fos, c-jun, and AP-1 activation through inhibition of p38 MAP kinase J. Cereb. Blood Flow Metab 2000, 20, 1077-1088
67. Impey, S.; Goodman, R. H. CREB signaling - timing is everything Sci. STKE 2001, 2001, PE1
68. Radley, E.; Akram, A.; Grubb, B. D.; Gibson, C. L. Investigation of the mechanisms of progesterone protection following oxygen-glucose deprivation in organotypic hippocampal slice cultures Neurosci. Lett. 2012, 506, 131-135
69. Whalley, B. J.; Stephens, G. J.; Constanti, A. Investigation of the effects of the novel anticonvulsant compound carisbamate (RWJ-333369) on rat piriform cortical neurones in vitro Br. J. Pharmacol. 2009, 156, 994-1008
70. Pond, B. B.; Berglund, K.; Kuner, T.; Feng, G.; Augustine, G. J.; Schwartz-Bloom, R. D. The chloride transporter Na(+)-K(+)-Cl- cotransporter isoform-1 contributes to intracellular chloride increases after in vitro ischemia J. Neurosci. 2006, 26, 1396-406
71. Gravielle, M. C.; Faris, R.; Russek, S. J.; Farb, D. H. GABA induces activity dependent delayed-onset uncoupling of GABA/benzodiazepine site interactions in neocortical neurons J. Biol. Chem. 2005, 280, 20954-60
72. Sedelnikova, A.; Erkkila, B. E.; Harris, H.; Zakharkin, S. O.; Weiss, D. S. Stoichiometry of a pore mutation that abolishes picrotoxin-mediated antagonism of the GABAA receptor J. Physiol. 2006, 577, 569-577
73. Korshoej, A. R.; Holm, M. M.; Jensen, K.; Lambert, J. D. Kinetic analysis of evoked IPSCs discloses mechanism of antagonism of synaptic GABAA receptors by picrotoxin Br. J. Pharmacol. 2010, 159, 636-649
74. Sceniak, M. P.; Maciver, M. B. Slow GABA(A) mediated synaptic transmission in rat visual cortex BMC Neurosci. 2008, 9, 8
75. Han, S. M.; Youn, D. H. GABAA receptor-mediated tonic currents in substantia gelatinosa neurons of rat spinal trigeminal nucleus pars caudalis Neurosci. Lett. 2008, 441, 296-301
76. Fletcher, J. T.; Walz, S. E.; Keeney, M. E. Monosubstituted 1,2,3-triazoles from two-step one-pot deprotection/click additions of trimethylsilylacetylene Tetrahedron Lett. 2008, 49, 7030-7032
77. Bender, D. M.; Peterson, J. A.; McCarthy, J. R.; Gunaydin, H.; Takano, Y.; Houk, K. N. Cyclopropanecarboxylic acid esters as potential prodrugs with enhanced hydrolytic stability Org. Lett. 2008, 10, 509-511
78. Buckell, F.; Hartry, J. D.; Rajalingam, U.; Bennett, B. M.; Whitney, R. A.; Thatcher, G. R. J. Hydrolysis of nitrite esters: putative intermediates in the biotransformation of organic nitrates J. Chem. Soc., Perkin Trans. 2 1994, 401-403
79. SantAngelo, A.; Trinchese, F.; Arancio, O. Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimers disease Neurochem. Res. 2003, 28, 1009-1015
80. Bliss, T. V.; Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus Nature 1993, 361, 31-39
81. Trinchese, F.; Liu, S.; Battaglia, F.; Walter, S.; Mathews, P. M.; Arancio, O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice Ann. Neurol. 2004, 55, 801-814
82. Gong, B.; Vitolo, O. V.; Trinchese, F.; Liu, S.; Shelanski, M.; Arancio, O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment J. Clin. Invest. 2004, 114, 1624-1634
83. Schindler, U. Pre-clinical evaluation of cognition enhancing drugs Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1989, 13 (Suppl.) S99-S115
84. Abdul-Hay, S.; Schiefer, I. T.; Chandrasena, R. E.; Li, M.; Abdelhamid, R.; Wang, Y. T.; Tavassoli, E.; Michalsen, B.; Asghodom, R. T.; Luo, J.; Thatcher, G. R. NO-SSRIs: nitric oxide chimera drugs incorporating a selective serotonin reuptake inhibitor ACS Med. Chem. Lett. 2011, 2, 656-661
85. Satoh, J.; Tabunoki, H.; Arima, K. Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus Dis. Markers 2009, 27, 239-252
86. Louzada, P. R.; Paula Lima, A. C.; Mendonca-Silva, D. L.; Noel, F.; De Mello, F. G.; Ferreira, S. T. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimers disease and other neurological disorders FASEB J. 2004, 18, 511-518
87. Lin, X.; Jun-Tian, Z. Neuroprotection by d -securinine against neurotoxicity induced by beta-amyloid (25-35) Neurol. Res. 2004, 26, 792-796
88. Lee, B. Y.; Ban, J. Y.; Seong, Y. H. Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells Neurosci. Res. 2005, 52, 347-356
89. Marcade, M.; Bourdin, J.; Loiseau, N.; Peillon, H.; Rayer, A.; Drouin, D.; Schweighoffer, F.; Desire, L. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing J. Neurochem. 2008, 106, 392-404
90. Ziakas, G. N.; Rekka, E. A.; Gavalas, A. M.; Eleftheriou, P. T.; Tsiakitzis, K. C.; Kourounakis, P. N. Nitric oxide releasing derivatives of tolfenamic acid with anti-inflammatory activity and safe gastrointestinal profile Bioorg. Med. Chem. 2005, 13, 6485-6492
91. Madrigal, J. L.; Feinstein, D. L.; Dello Russo, C. Norepinephrine protects cortical neurons against microglial-induced cell death J. Neurosci. Res. 2005, 81, 390-396
92. Canas, P. T.; Velly, L. J.; Labrande, C. N.; Guillet, B. A.; Sautou-Miranda, V.; Masmejean, F. M.; Nieoullon, A. L.; Gouin, F. M.; Bruder, N. J.; Pisano, P. S. Sevoflurane protects rat mixed cerebrocortical neuronal-glial cell cultures against transient oxygen-glucose deprivation: involvement of glutamate uptake and reactive oxygen species Anesthesiology 2006, 105, 990-998
93. Schubert, D.; Piasecki, D. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade J. Neurosci. 2001, 21, 7455-7462
94. Ha, J. S.; Lee, C. S.; Maeng, J. S.; Kwon, K. S.; Park, S. S. Chronic glutamate toxicity in mouse cortical neuron culture Brain Res. 2009, 1273, 138-143
95. Abdelhamid, R.; Luo, J.; Vandevrede, L.; Kundu, I.; Michalsen, B.; Litosh, V. A.; Schiefer, I. T.; Gherezghiher, T.; Yao, P.; Qin, Z.; Thatcher, G. R. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism ACS Chem. Neurosci. 2011, 2, 256-268